DYSREGULATED EXPRESSION OF THE T-CELL CYTOKINE ETA-1 IN CD4-8- LYMPHOCYTES DURING THE DEVELOPMENT OF MURINE AUTOIMMUNE-DISEASE

被引:80
作者
PATARCA, R [1 ]
WEI, FY [1 ]
SINGH, P [1 ]
MORASSO, MI [1 ]
CANTOR, H [1 ]
机构
[1] HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT PATHOL, IMMUNOPATHOL LAB,44 BINNEY ST,D730, BOSTON, MA 02115 USA
关键词
D O I
10.1084/jem.172.4.1177
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of autoimmune disease in the MRL/MpJ-lpr inbred mouse strain depends upon the maturation of a subset of T lymphocytes that may cause sustained activation of immunological effector cells such as B cells and macrophages. We tested the hypothesis that abnormal effector cell activation reflects constitutive overexpression of a T cell cytokine. We found that a newly defined T cell cytokine, Eta-1, is expressed at very high levels in T cells from MRL/1 mice but not normal mouse strains and in a CD4−8− 45R+ T cell clone. The Eta-1 gene encodes a secreted protein that binds specifically to macrophages, possibly via a cell adhesion receptor, resulting in alterations in the mobility and activation state of this cell type (Patarca, R., G. J. Freeman, R. P. Singh, et al. 1989. J. Exp. Med. 170:145; Singh, R. P., R. Patarca, J. Schwartz, P. Singh, and H. Cantor. 1990. J. Exp. Med. 171: 1931). In addition, recent studies have indicated that Eta-1 can enhance secretion of IgM and IgG by mixtures of macrophages and B cells (Patarca, R., M. A. Lampe, M. V. Iregai, and H. Cantor, manuscript in preparation). Deregulation of Eta-1 expression begins at the onset of autoimmune disease and continues throughout the course of this disorder. Maximal levels of Eta-1 expression and the development of severe autoimmune disease reflect the combined contribution of the Ipr gene and MRL background genes. © 1990, Rockefeller University Press., All rights reserved.
引用
收藏
页码:1177 / 1183
页数:7
相关论文
共 24 条
[1]   SPONTANEOUS MURINE LUPUS-LIKE SYNDROMES - CLINICAL AND IMMUNOPATHOLOGICAL MANIFESTATIONS IN SEVERAL STRAINS [J].
ANDREWS, BS ;
EISENBERG, RA ;
THEOFILOPOULOS, AN ;
IZUI, S ;
WILSON, CB ;
MCCONAHEY, PJ ;
MURPHY, ED ;
ROTHS, JB ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (05) :1198-1215
[2]  
BOSWELL JM, 1988, J IMMUNOL, V141, P3050
[3]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[4]  
DAVIGNON JL, 1985, J IMMUNOL, V135, P2423
[5]   HUMAN B-CELL DIFFERENTIATION FACTOR DEFINED BY AN ANTIPEPTIDE ANTIBODY AND ITS POSSIBLE ROLE IN AUTOANTIBODY PRODUCTION [J].
HIRANO, T ;
TAGA, T ;
YASUKAWA, K ;
NAKAJIMA, K ;
NAKANO, N ;
TAKATSUKI, F ;
SHIMIZU, M ;
MURASHIMA, A ;
TSUNASAWA, S ;
SAKIYAMA, F ;
KISHIMOTO, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (01) :228-231
[6]   UNIQUE STRUCTURE OF MURINE INTERLEUKIN-2 AS DEDUCED FROM CLONED CDNAS [J].
KASHIMA, N ;
NISHITAKAOKA, C ;
FUJITA, T ;
TAKI, S ;
YAMADA, G ;
HAMURO, J ;
TANIGUCHI, T .
NATURE, 1985, 313 (6001) :402-404
[7]   DELETION OF POTENTIALLY SELF-REACTIVE T-CELL RECEPTOR SPECIFICITIES IN L3T4-, LYT-2- T-CELLS OF LPR MICE [J].
KOTZIN, BL ;
BABCOCK, SK ;
HERRON, LR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (06) :2221-2229
[8]  
MORSE HC, 1982, J IMMUNOL, V129, P2612
[9]   AUTOIMMUNITY AND INCREASED C-MYB TRANSCRIPTION [J].
MOUNTZ, JD ;
STEINBERG, AD ;
KLINMAN, DM ;
SMITH, HR ;
MUSHINSKI, JF .
SCIENCE, 1984, 226 (4678) :1087-1089
[10]  
MURAY LJ, EUR J IMMUNOL, V20, P163